塞来昔布-话题@MedSci

#塞来昔布#

26篇内容 | 1618人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2110701, encodeId=fb3a2110e01dc, content=<a href='/topic/show?id=9b4751449d' target=_blank style='color:#2F92EE;'>#COX-2抑制剂#</a><a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>是<a href='/topic/show?id=65b05806579' target=_blank style='color:#2F92EE;'>#新冠病毒#</a>阳性患者早期症状<a href='/topic/show?id=ab68105111e0' target=_blank style='color:#2F92EE;'>#居家管理#</a>首选药物, objectTitle=【重磅】《柳叶刀•感染病学》：COX-2抑制剂塞来昔布是新冠阳性患者早期症状居家管理首选药物, objectType=article, longId=756383, objectId=b635e5638353, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230117/1673940093675_8252897.jpg, objectUrl=/article/show_article.do?id=b635e5638353, replyNumber=0, likeNumber=97, createdTime=2023-01-18, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b635e5638353, moduleTitle=【重磅】《柳叶刀•感染病学》：COX-2抑制剂塞来昔布是新冠阳性患者早期症状居家管理首选药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b635e5638353)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283839, encodeId=3467128383977, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=吲哚美辛、美洛昔康、塞来昔布……选择治疗强直的非甾体抗炎药应该注意什么？, objectType=article, longId=724925, objectId=ea42e249250a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea42e249250a, replyNumber=0, likeNumber=0, createdTime=2022-04-26, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea42e249250a, moduleTitle=吲哚美辛、美洛昔康、塞来昔布……选择治疗强直的非甾体抗炎药应该注意什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea42e249250a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283838, encodeId=167e1283838f6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=EHJCP：塞来昔布与萘普生或布洛芬治疗关节炎的心肾风险比较, objectType=article, longId=301446, objectId=6eb23014462f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eb23014462f, replyNumber=0, likeNumber=68, createdTime=2022-03-24, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eb23014462f, moduleTitle=EHJCP：塞来昔布与萘普生或布洛芬治疗关节炎的心肾风险比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eb23014462f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283837, encodeId=fe99128383e80, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=吲哚美辛、美洛昔康、塞来昔布……AS的非甾体抗炎药如何选择, objectType=article, longId=293911, objectId=76592939112a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76592939112a, replyNumber=0, likeNumber=61, createdTime=2022-01-14, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76592939112a, moduleTitle=吲哚美辛、美洛昔康、塞来昔布……AS的非甾体抗炎药如何选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76592939112a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283836, encodeId=57bd1283836a6, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=JAMA：塞来昔布联合FOLFOX标准辅助化疗对结肠癌患者无病生存率的影响, objectType=article, longId=209666, objectId=658c209666ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=658c209666ea, replyNumber=0, likeNumber=46, createdTime=2021-04-09, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=658c209666ea, moduleTitle=JAMA：塞来昔布联合FOLFOX标准辅助化疗对结肠癌患者无病生存率的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=658c209666ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283835, encodeId=3cce1283835b5, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率, objectType=article, longId=196693, objectId=dce7196693fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dce7196693fd, replyNumber=0, likeNumber=45, createdTime=2020-06-30, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dce7196693fd, moduleTitle=AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dce7196693fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283834, encodeId=22bc1283834a9, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=Pharmacotherapy：塞来昔布治疗骨关节炎患者健康相关生活质量的功能状态评估, objectType=article, longId=193987, objectId=7fac19398e67, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fac19398e67, replyNumber=0, likeNumber=47, createdTime=2020-05-13, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fac19398e67, moduleTitle=Pharmacotherapy：塞来昔布治疗骨关节炎患者健康相关生活质量的功能状态评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fac19398e67)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283833, encodeId=fd76128383395, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=J Rheumatol：连续与间歇性塞来昔布治疗骨性关节炎的疗效, objectType=article, longId=193985, objectId=969219398508, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=969219398508, replyNumber=0, likeNumber=44, createdTime=2020-05-13, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=969219398508, moduleTitle=J Rheumatol：连续与间歇性塞来昔布治疗骨性关节炎的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=969219398508)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283832, encodeId=efb41283832e3, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=JCLA：塞来昔布治疗前后膝关节骨性关节炎患者miRNA表达谱的变化, objectType=article, longId=167453, objectId=8f3116e4536c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f3116e4536c, replyNumber=0, likeNumber=52, createdTime=2019-06-03, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f3116e4536c, moduleTitle=JCLA：塞来昔布治疗前后膝关节骨性关节炎患者miRNA表达谱的变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f3116e4536c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283831, encodeId=695012838316c, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=J Natl Cancer Inst：塞来昔布联用阿司匹林是绝经后激素受体阳性乳腺癌患者的福音？, objectType=article, longId=151815, objectId=b9ac151815da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9ac151815da, replyNumber=0, likeNumber=51, createdTime=2018-10-26, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9ac151815da, moduleTitle=J Natl Cancer Inst：塞来昔布联用阿司匹林是绝经后激素受体阳性乳腺癌患者的福音？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9ac151815da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283830, encodeId=349c1283830c9, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=塞来昔布显示对Duchenne型肌营养不良的潜在益处, objectType=article, longId=137946, objectId=eaa613e9464e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eaa613e9464e, replyNumber=0, likeNumber=55, createdTime=2018-05-13, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eaa613e9464e, moduleTitle=塞来昔布显示对Duchenne型肌营养不良的潜在益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eaa613e9464e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283829, encodeId=d7a212838299d, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, objectType=article, longId=125185, objectId=de17125185b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de17125185b2, replyNumber=0, likeNumber=41, createdTime=2018-01-01, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de17125185b2, moduleTitle=EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de17125185b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283828, encodeId=5ba81283828f2, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=Lancet：心脏血栓性疾病联合关节炎患者：塞来昔布vs萘普生, objectType=article, longId=104951, objectId=2e241049515d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e241049515d, replyNumber=0, likeNumber=45, createdTime=2017-07-09, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e241049515d, moduleTitle=Lancet：心脏血栓性疾病联合关节炎患者：塞来昔布vs萘普生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e241049515d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283827, encodeId=c575128382ea8, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=Lancet：塞来昔布联合质子泵抑制剂可以减少上消化道出血风险, objectType=article, longId=95573, objectId=a629955e310, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a629955e310, replyNumber=0, likeNumber=42, createdTime=2017-04-14, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a629955e310, moduleTitle=Lancet：塞来昔布联合质子泵抑制剂可以减少上消化道出血风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a629955e310)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283826, encodeId=616c128382680, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=NEJM：塞来昔布心血管安全性不比萘普生或布洛芬差, objectType=article, longId=82351, objectId=fdfb823516a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdfb823516a, replyNumber=0, likeNumber=38, createdTime=2016-11-15, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdfb823516a, moduleTitle=NEJM：塞来昔布心血管安全性不比萘普生或布洛芬差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdfb823516a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283825, encodeId=1fed128382526, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=JNCI：虽然塞来昔布能预防结直肠腺瘤复发，但心血管毒性不容忽视, objectType=article, longId=78126, objectId=111fe8126dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=111fe8126dc, replyNumber=0, likeNumber=52, createdTime=2016-09-23, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=111fe8126dc, moduleTitle=JNCI：虽然塞来昔布能预防结直肠腺瘤复发，但心血管毒性不容忽视, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=111fe8126dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283824, encodeId=307b1283824d4, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=Cancer Res：COX-2抑制剂塞来昔布可能具有抗癌作用, objectType=article, longId=69366, objectId=5df56936690, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5df56936690, replyNumber=0, likeNumber=41, createdTime=2016-05-30, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5df56936690, moduleTitle=Cancer Res：COX-2抑制剂塞来昔布可能具有抗癌作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5df56936690)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283823, encodeId=af4d12838234a, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=ESC 2015：塞来昔布到底可否用于心血管疾病人群（SCOT试验）？, objectType=article, longId=56120, objectId=6c31561203c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c31561203c, replyNumber=0, likeNumber=41, createdTime=2015-09-14, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c31561203c, moduleTitle=ESC 2015：塞来昔布到底可否用于心血管疾病人群（SCOT试验）？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c31561203c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283822, encodeId=8ad912838229f, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=全膝关节置换围术期塞来昔布镇痛疗效评估, objectType=article, longId=45262, objectId=f29b45262a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f29b45262a2, replyNumber=0, likeNumber=47, createdTime=2015-01-11, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f29b45262a2, moduleTitle=全膝关节置换围术期塞来昔布镇痛疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f29b45262a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1283821, encodeId=07801283821a0, content=<a href='/topic/show?id=082842228d3' target=_blank style='color:#2F92EE;'>#塞来昔布#</a>, objectTitle=Rheumatology：印度传统药物治疗膝骨关节炎疗效近似于氨基葡萄糖和塞来昔布, objectType=article, longId=27006, objectId=85ab2e00690, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ab2e00690, replyNumber=0, likeNumber=55, createdTime=2013-11-25, rootId=0, userName=xiongke010, userId=ce68183, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ab2e00690, moduleTitle=Rheumatology：印度传统药物治疗膝骨关节炎疗效近似于氨基葡萄糖和塞来昔布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85ab2e00690)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

塞来昔布

2020-05-29

showtest (审核中...)

前往app查看评论内容

#COX-2抑制剂##塞来昔布#是#新冠病毒#阳性患者早期症状#居家管理#首选药物

【重磅】《柳叶刀•感染病学》：COX-2抑制剂塞来昔布是新冠阳性患者早期症状居家管理首选药物

2023-01-18发表于上海

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

吲哚美辛、美洛昔康、塞来昔布……选择治疗强直的非甾体抗炎药应该注意什么？

2022-04-26

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

EHJCP：塞来昔布与萘普生或布洛芬治疗关节炎的心肾风险比较

2022-03-24

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

吲哚美辛、美洛昔康、塞来昔布……AS的非甾体抗炎药如何选择

2022-01-14

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

JAMA：塞来昔布联合FOLFOX标准辅助化疗对结肠癌患者无病生存率的影响

2021-04-09

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

AACR 2020：塞来昔布降低了肝癌患者索拉非尼相关手足综合征的发病率

2020-06-30

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

Pharmacotherapy：塞来昔布治疗骨关节炎患者健康相关生活质量的功能状态评估

2020-05-13

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

J Rheumatol：连续与间歇性塞来昔布治疗骨性关节炎的疗效

2020-05-13

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

JCLA：塞来昔布治疗前后膝关节骨性关节炎患者miRNA表达谱的变化

2019-06-03

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

J Natl Cancer Inst：塞来昔布联用阿司匹林是绝经后激素受体阳性乳腺癌患者的福音？

2018-10-26

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

塞来昔布显示对Duchenne型肌营养不良的潜在益处

2018-05-13

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

EUR J Cancer：化疗联合塞来昔布或曲妥珠单抗治疗乳腺癌患者的多中心随机II期临床试验

2018-01-01

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

Lancet：心脏血栓性疾病联合关节炎患者：塞来昔布vs萘普生

2017-07-09

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

Lancet：塞来昔布联合质子泵抑制剂可以减少上消化道出血风险

2017-04-14

一叶知秋 (审核中...)

前往app查看评论内容

#塞来昔布#

NEJM：塞来昔布心血管安全性不比萘普生或布洛芬差

2016-11-15

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

JNCI：虽然塞来昔布能预防结直肠腺瘤复发，但心血管毒性不容忽视

2016-09-23

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

Cancer Res：COX-2抑制剂塞来昔布可能具有抗癌作用

2016-05-30

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

ESC 2015：塞来昔布到底可否用于心血管疾病人群（SCOT试验）？

2015-09-14

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

全膝关节置换围术期塞来昔布镇痛疗效评估

2015-01-11

xiongke010 (审核中...)

前往app查看评论内容

#塞来昔布#

Rheumatology：印度传统药物治疗膝骨关节炎疗效近似于氨基葡萄糖和塞来昔布

2013-11-25

科室
- - 订阅+
  - 更多科室
工具
服务